RJB 0402
Alternative Names: RJB-0402Latest Information Update: 29 Apr 2024
At a glance
- Originator Rejuvenate Bio
- Developer Rejuvenate Bio; Rejuvenate Biomed
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Fibroblast growth factor 21 expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiomyopathies; Familial partial lipodystrophy
Most Recent Events
- 29 Apr 2024 Preclinical trials in Familial partial lipodystrophy in USA (Parenteral), before April 2024 (Rejuvenate Bio pipeline, April 2024)
- 09 Oct 2023 Preclinical trials in Cardiomyopathies in USA (Parenteral)
- 09 Oct 2023 Rejuvenate Bio plans a clinical trial for Desmoplakin-related arrhythmogenic cardiomyopathy (Parenteral)